Literature DB >> 11179365

Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.

T A Pitcovsky1, J Mucci, P Alvarez, M S Leguizamón, O Burrone, P M Alzari, O Campetella.   

Abstract

Trypanosoma cruzi, the agent of Chagas' disease, expresses trans-sialidase, a unique enzyme activity that enables the parasite to invade host cells by transferring sialyl residues from host glyconjugates to the parasite's surface acceptor molecules. The enzyme is also shed into the surrounding environment, causing apoptosis in cells from the immune system. During infections, an antibody response against the catalytic region of the trans-sialidase that is coincident with the control of the parasitemia and survival of the host is observed. This low-titer humoral response is characterized by its persistence for many years in benznidazole-treated patients. Here we analyzed the antigenic structure of the molecule by phage-displayed peptide combinatorial libraries and SPOT synthesis. Several epitopes were defined and located on the three-dimensional model of the enzyme. Unexpectedly, cross-reaction was found among several epitopes distributed in different locations displaying nonconsensus sequences. This finding was confirmed by the reactivity of three monoclonal antibodies able to recognize non-sequence-related peptides that together constitute the surface surrounding the catalytic site of the enzyme. The presence of cross-reacting epitopes within a single molecule suggests a mechanism developed to avoid a strong humoral response by displaying an undefined target to the immune system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179365      PMCID: PMC98094          DOI: 10.1128/IAI.69.3.1869-1875.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides.

Authors:  A Luzzago; F Felici; A Tramontano; A Pessi; R Cortese
Journal:  Gene       Date:  1993-06-15       Impact factor: 3.688

2.  Structural basis of sialyltransferase activity in trypanosomal sialidases.

Authors:  A Buschiazzo; G A Tavares; O Campetella; S Spinelli; M L Cremona; G París; M F Amaya; A C Frasch; P M Alzari
Journal:  EMBO J       Date:  2000-01-04       Impact factor: 11.598

Review 3.  The immunology of malaria infection.

Authors:  M Plebanski; A V Hill
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

4.  Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.

Authors:  V L Pereira-Chioccola; F Costa; M Ribeirão; I S Soares; F Arena; S Schenkman; M M Rodrigues
Journal:  Parasite Immunol       Date:  1999-02       Impact factor: 2.280

5.  Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.

Authors:  M S Leguizamón; G Russomando; A Rojas de Arias; M Samudio; M Cabral; S M González-Cappa; A C Frasch; O Campetella
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

6.  Bloodstream Trypanosoma cruzi parasites from mice simultaneously express antigens that are markers of acute and chronic human Chagas disease.

Authors:  M S Leguizamon; O E Campetella; M B Reyes; C F Ibañez; M A Basombrio; J Rincon; A Orn; A C Frasch
Journal:  Parasitology       Date:  1991-06       Impact factor: 3.234

7.  Incorporation of sialic acid into Trypanosoma cruzi macromolecules. A proposal for a new metabolic route.

Authors:  J O Previato; A F Andrade; M C Pessolani; L Mendonça-Previato
Journal:  Mol Biochem Parasitol       Date:  1985-06       Impact factor: 1.759

8.  Mediation of Trypanosoma cruzi invasion by sialic acid on the host cell and trans-sialidase on the trypanosome.

Authors:  M Ming; M Chuenkova; E Ortega-Barria; M E Pereira
Journal:  Mol Biochem Parasitol       Date:  1993-06       Impact factor: 1.759

Review 9.  Structural and functional properties of Trypanosoma trans-sialidase.

Authors:  S Schenkman; D Eichinger; M E Pereira; V Nussenzweig
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

10.  Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.

Authors:  M Chuenkova; M E Pereira
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  18 in total

1.  Multiple overlapping epitopes in the repetitive unit of the shed acute-phase antigen from Trypanosoma cruzi enhance its immunogenic properties.

Authors:  P Alvarez; M S Leguizamón; C A Buscaglia; T A Pitcovsky; O Campetella
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 2.  Combinatorial chemistry as a new approach in antiparasitic drug discovery.

Authors:  Andreas Link
Journal:  Parasitol Res       Date:  2003-05-07       Impact factor: 2.289

3.  Subtractive phage display selection from canine visceral leishmaniasis identifies novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications.

Authors:  Lourena E Costa; Mayara I S Lima; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Vivian T Martins; Mariana C Duarte; Paula S Lage; Eliane G P Lopes; Daniela P Lage; Tatiana G Ribeiro; Pedro H R Andrade; Danielle F de Magalhães-Soares; Manuel Soto; Carlos A P Tavares; Luiz R Goulart; Eduardo A F Coelho
Journal:  Clin Vaccine Immunol       Date:  2013-11-20

4.  Mapping of B-cell epitopes in a Trypanosoma cruzi immunodominant antigen expressed in natural infections.

Authors:  Mylène Lesénéchal; Laurence Becquart; Xavier Lacoux; Laurent Ladavière; Renata C P Baida; Glaucia Paranhos-Baccalà; José Franco da Silveira
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

5.  Epidemiological profiles of human immunodeficiency virus and hepatitis C virus infections in Malian women: Risk factors and relevance of disparities.

Authors:  Nouhoum Bouare; Andre Gothot; Jean Delwaide; Sebastien Bontems; Dolores Vaira; Laurence Seidel; Paul Gerard; Christiane Gerard
Journal:  World J Hepatol       Date:  2013-04-27

Review 6.  Parasite-host glycan interactions during Trypanosoma cruzi infection: trans-Sialidase rides the show.

Authors:  Oscar Campetella; Carlos A Buscaglia; Juan Mucci; María Susana Leguizamón
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-20       Impact factor: 5.187

7.  Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors.

Authors:  Alejandro Buschiazzo; Romina Muiá; Nicole Larrieux; Tamara Pitcovsky; Juan Mucci; Oscar Campetella
Journal:  PLoS Pathog       Date:  2012-01-05       Impact factor: 6.823

8.  A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease.

Authors:  André Azevedo Reis Teixeira; Luis Rodriguez Carnero; Andréia Kuramoto; Fenny Hui Fen Tang; Carlos Hernique Gomes; Natalia Bueno Pereira; Léa Campos de Oliveira; Regina Garrini; Jhonatas Sirino Monteiro; João Carlos Setubal; Ester Cerdeira Sabino; Renata Pasqualini; Walter Colli; Wadih Arap; Maria Júlia Manso Alves; Edécio Cunha-Neto; Ricardo José Giordano
Journal:  iScience       Date:  2021-05-15

9.  The MASP family of Trypanosoma cruzi: changes in gene expression and antigenic profile during the acute phase of experimental infection.

Authors:  Sara Lopes dos Santos; Leandro Martins Freitas; Francisco Pereira Lobo; Gabriela Flávia Rodrigues-Luiz; Tiago Antônio de Oliveira Mendes; Anny Carolline Silva Oliveira; Luciana Oliveira Andrade; Egler Chiari; Ricardo Tostes Gazzinelli; Santuza Maria Ribeiro Teixeira; Ricardo Toshio Fujiwara; Daniella Castanheira Bartholomeu
Journal:  PLoS Negl Trop Dis       Date:  2012-08-14

10.  Selection of binding targets in parasites using phage-display and aptamer libraries in vivo and in vitro.

Authors:  R R Tonelli; W Colli; M J M Alves
Journal:  Front Immunol       Date:  2013-01-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.